British pharmaceutical company AstraZeneca will pay the Japanese Daiichi Sankyo of up to $ 6 billion for an experimental drug DS-1062, used for treatment of malignant tumors. Under the agreement, the initial payment will be $ 1 billion, writes Reuters.
DS-1062 is a promising class of conjugates of monoclonal antibody and drug. In AstraZeneca expects that the drug will be effective in the treatment of lung cancer, breast cancer and other tumor types, which are characterized by the expression of TROP2.
According to analysts JP Morgan, in case of successful registration DS-1062, sales of the drug may be about $ 1 billion a year.
This is not the first cooperation agreement between AstraZeneca and Daiichi Sankyo. In March of 2019, the parties agreed on the development and marketing of anticancer trastuzumab dioxacine, the amount of the payment transaction may reach 6.9 billion dollars. Recently, the FDA approved the drug for the treatment of inoperable or metastatic HER2-positive breast cancer.